| Website | vantiatherapeutic... |
| Category | BioTech |
| Phone | +44 23 8076 3400 |
| info@vantia.com | |
| Employees |
| TOTAL | $6.5M |
| FUNDING TOTAL | $6.5M |
| Series B, 7/11 Novo A/S SV Life Sciences MVM Life Science Partners | $6.5M |
Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia’s strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
